WSIB Coverage for Psychedelic-Assisted Therapy in Ontario (2026)

If you are an injured worker or first responder in Ontario with an accepted PTSD or chronic-pain claim, this guide explains how WSIB handles ketamine-based therapy: which drugs are listed, how prior authorization works, how presumptive PTSD legislation fits in, and how to apply.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

Key takeaways

• WSIB lists ketamine HCl injection on several specialty formularies and esketamine nasal spray (Spravato) on two. Every listing requires prior authorization. WSIB decides each request; coverage is never automatic. Confirm the current listings and criteria with the board.
• The covered conditions are Complex Regional Pain Syndrome (CRPS), refractory neuropathic pain, and treatment-resistant depression (TRD). PTSD is not a listed indication. Ketamine for PTSD remains off-label and is not guideline-supported.
• Ontario's Supporting Ontario's First Responders Act, 2016 (Bill 163) gives designated first responders a legal presumption that their PTSD is work-related. This speeds up the underlying claim. It does not approve any specific treatment.
• Later amendments expanded the presumptive list to include wildland firefighters and wildland fire investigators. Confirm the current designated categories with WSIB.
• Psilocybin and MDMA are not on any WSIB formulary. Legal access requires Health Canada approval on a case-by-case basis, initiated by a physician, and approval is not guaranteed.
• WSIB coverage is claim-by-claim and formulary-dependent. ATMA CENA supports your application; WSIB makes the coverage decision.

If you have a WSIB-accepted claim and want to understand your options, you can book a free information call to discuss your specific situation with ATMA CENA's clinical team.

---

Does WSIB cover ketamine and esketamine in Ontario?

WSIB Ontario offers one of the most structured workers' compensation pathways in Canada for ketamine-based treatment, but coverage is conditional, not automatic. The WSIB Drug Benefit Program lists both ketamine HCl injection and esketamine nasal spray (Spravato) on specialty formularies, each requiring prior authorization. Your treating physician must submit a request showing that your accepted work-related condition meets the formulary criteria, that conventional treatments have been tried and documented, and that the proposed drug fits the relevant indication. WSIB reviews each request and decides. ATMA CENA can support the clinical preparation around a request; it does not submit the request and does not decide coverage. The Drug Benefit Program covers prescription drugs needed for an accepted work-related injury or illness, and non-formulary drugs may be considered case by case through the prior authorization process [WSIB 2025].

---

Which WSIB formularies list ketamine and esketamine?

WSIB maps each drug to specific work-related injury types and clinical indications. The distinction matters: a worker with CRPS follows a different formulary pathway than a worker with TRD arising from a psychotraumatic workplace injury. WSIB first listed both drugs in 2023 and has updated its formulary listing decisions page since. The overall structure (several formularies for ketamine, two for esketamine, and the same three indications) has stayed consistent, but formulary codes and criteria can change, so confirm the current listings and criteria with the board before relying on them [WSIB 2025].

Ketamine HCl injection (Ketalar and generics)

Ketamine HCl injection is listed on several WSIB specialty formularies, all with prior authorization. As a general guide, the listed formularies and their covered work-related conditions are:

Formulary	Covered work-related conditions
Musculoskeletal	CRPS, refractory neuropathic pain
CNS/PNS	CRPS, refractory neuropathic pain
Psychotraumatic	TRD (in the context of a psychotraumatic injury)
Chronic Pain Disability	CRPS, refractory neuropathic pain
Serious Injury	TRD, CRPS, refractory neuropathic pain

Confirm the exact formulary codes and current mapping with WSIB, as these are periodically updated.

Esketamine nasal spray (Spravato)

Esketamine HCl nasal spray (Spravato) is listed on two WSIB formularies, both with prior authorization:

Formulary	Covered work-related conditions
Psychotraumatic	TRD (in the context of a psychotraumatic injury)
Serious Injury	TRD

What prior authorization generally asks for

WSIB publishes prior-authorization criteria for each indication. The general shape below reflects the published criteria as confirmed in the fact-check review; WSIB periodically refines this wording, so confirm the current text with the board before any request is submitted.

For CRPS (ketamine HCl only):

• A CRPS diagnosis meeting recognized diagnostic criteria
• Documented failure of non-drug and drug treatments
• Average pain rating at or above 4 out of 10

For refractory neuropathic pain (ketamine HCl only):

• A confirmed neuropathic pain diagnosis
• Pain lasting at least three months
• Average pain rating at or above 4 out of 10
• Failure of multiple first- and second-line medications at maximally tolerated doses

For treatment-resistant depression (both drugs):

• Inadequate response to at least two oral antidepressants at maximally tolerated doses
• Screening for contraindications and administration by a qualified specialist with appropriate monitoring
• An initial approval period of about six months, with renewal requiring evidence of response on a validated scoring tool

Watch out: WSIB periodically refines the prior-authorization criteria wording, including how and where certain forms of ketamine must be administered. Confirm the current details with the board before your physician prepares a request, so the application matches the current rules rather than an older version.

Important distinction on the Psychotraumatic formulary: This formulary covers TRD that arises in the setting of a psychotraumatic work-related injury. That is not the same as using ketamine to treat PTSD symptoms directly. The clinical evidence for ketamine as a direct PTSD treatment is still early, and VA/DoD clinical guidelines do not recommend ketamine for PTSD specifically [Feder 2021; CADTH 2023]. A worker with accepted PTSD and co-existing TRD may qualify under the Psychotraumatic formulary for the TRD indication, but the documentation has to reflect TRD, not PTSD symptom reduction alone.

Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label, regulated in Ontario by the College of Physicians and Surgeons of Ontario (CPSO). The evidence base differs by indication, and the sections below summarize it for PTSD and for chronic pain.

---

What does Ontario's presumptive PTSD legislation do for your claim?

Ontario's Supporting Ontario's First Responders Act, 2016 (Bill 163) creates a legal presumption that PTSD diagnosed in a designated first responder arose out of and in the course of their employment. In practice, the burden of proof shifts. A designated worker does not have to prove the PTSD is work-related; WSIB would have to show the work was not a significant contributing factor to deny on causation grounds. WSIB documents this in its Operational Policy Manual, Policy 15-03-13 (Posttraumatic Stress Disorder in First Responders and Other Designated Workers); confirm the current policy version and effective date with WSIB [WSIB 2026].

What presumptive PTSD legislation does:

• Speeds up the accepted PTSD diagnosis and the underlying WSIB claim
• Removes the worker's burden of proving the PTSD is work-related
• Gets you to mental-health treatment faster, because the claim is established sooner

What presumptive PTSD legislation does not do:

• It does not auto-approve any specific treatment, including ketamine or esketamine
• It does not override the formulary prior-authorization requirements
• Each treatment request still needs clinical justification meeting the relevant formulary criteria

For a worker with accepted PTSD who also meets the TRD criteria on the Psychotraumatic formulary, the presumption speeds up Step 1 of the application (establishing the accepted diagnosis). Steps 2 through 6 still apply.

---

Who counts as a designated first responder in Ontario?

WSIB Policy 15-03-13 lists the designated worker categories eligible for presumptive PTSD coverage; confirm the current list and its effective date with WSIB [WSIB 2026]. The original 2016 list under Bill 163 has been expanded by later amendments, most recently to add wildland firefighters and wildland fire investigators.

Designated categories generally include:

From Bill 163 (2016) and subsequent amendments:

• Full-time, part-time, and volunteer firefighters
• Fire investigators
• Police officers
• Emergency response team members
• Paramedics and emergency medical attendants
• Ambulance service managers
• 911 emergency-response dispatch workers
• Nurses providing direct patient care (in certain settings)
• Correctional and secure-custody/detention facility workers
• Provincial bailiffs, probation officers, and supervisors of probation officers
• Special constables
• Forensic and crime-analysis unit police members

Added by later amendment:

• Wildland firefighters
• Wildland fire investigators

Industrial workers, agricultural workers, and other WSIB-covered occupations outside this list still follow the standard path: they document the work-relatedness of their PTSD diagnosis. That can take more clinical documentation, but it is achievable.

The wildland expansion responded to growing recognition of trauma exposure among wildland firefighters and investigators facing more severe fire seasons. Transitional provisions applied to claims filed within a defined window; confirm the current eligibility details and any transitional cut-off with WSIB.

---

What does the evidence say about ketamine for work-related PTSD and pain?

The evidence base differs by condition, and the WSIB formulary reflects that. Read it honestly: the support is stronger for pain than for PTSD.

Ketamine for PTSD: emerging, not established

A 2021 randomized controlled trial by Feder and colleagues in the American Journal of Psychiatry gave the first direct RCT evidence for repeated ketamine infusions in chronic PTSD. In 30 participants, 67% of the ketamine group achieved at least a 30% symptom reduction versus 20% in the midazolam comparison group [Feder 2021, PMID 33397139]. That is a meaningful early signal, but 30 participants is a small trial, and a single small study does not establish a treatment.

A 2023 CADTH rapid review found the evidence does not support ketamine for PTSD per VA/DoD clinical guidelines, with mixed findings across small RCTs [CADTH 2023]. The honest picture: ketamine for PTSD has a plausible and growing evidence base, but it is not guideline-supported for that indication. This is exactly why the WSIB formulary covers ketamine for TRD (including TRD that arises after a psychotraumatic injury), not for PTSD symptom reduction on its own.

Ketamine for CRPS and neuropathic pain: a stronger base

The evidence for ketamine in CRPS and refractory neuropathic pain is more established, which is why WSIB lists ketamine for these conditions on its pain-related specialty formularies. Workers with accepted CRPS or refractory neuropathic pain have the clearest route to WSIB ketamine coverage.

MDMA-assisted therapy: strongest PTSD evidence, but not WSIB-covered

For PTSD specifically, MDMA-assisted therapy has the strongest phase 3 trial evidence. In the MAPP1 trial, a majority of MDMA-group participants no longer met PTSD criteria at study end, outperforming placebo [Mitchell 2021]. A confirmatory MAPP2 trial reported MDMA outperforming placebo on PTSD severity and functional impairment [Mitchell 2023, PMID 37709999]. Despite this, MDMA is not on any WSIB formulary. The only access route is Health Canada's case-by-case authorization, initiated by a physician, explained below.

---

Does WSIB cover psilocybin or MDMA?

Psilocybin and MDMA are not listed on any Canadian workers' compensation formulary, including WSIB Ontario. They are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy requires Health Canada approval on a case-by-case basis, initiated by a physician, and approval is not guaranteed. Requests for psilocybin are primarily considered for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. Requests for MDMA are primarily considered for adults with PTSD.

Since January 2022, Health Canada has accepted physician-initiated requests for psilocybin and MDMA, but the realistic 2026 picture is sobering. PsyCan, using data released under the Access to Information Act, reported that these approvals dropped roughly 50% in 2025, with longer decision timelines [PsyCan 2025].

For Ontario workers considering psilocybin or MDMA through this pathway, the practical reality is:

• Access is theoretically possible for PTSD (MDMA) or TRD (psilocybin)
• Workers' compensation would not directly fund therapy accessed this way at this time
• The application is complex, approval is uncertain, and timelines are long
• WSIB ketamine and esketamine coverage remains the most actionable work-related pathway

---

How to apply for WSIB coverage for ketamine therapy in Ontario

The path to WSIB ketamine or esketamine coverage follows a defined sequence. The steps below reflect the general process; your individual claim may vary based on the accepted injury, the formulary, and your clinical history.

Step 1: Establish the accepted diagnosis. Your WSIB claim must be accepted, and the work-related condition (CRPS, refractory neuropathic pain, or TRD linked to a psychotraumatic injury) must be established. For designated first responders, Bill 163 creates a presumption of work-relatedness that speeds this up. Other workers document work-relatedness through the standard WSIB process.

Step 2: Identify a prescribing physician in Ontario. Ketamine for psychiatric and pain indications requires a physician with the knowledge, skill, and judgment to prescribe it safely, as CPSO policy requires. Intravenous and intramuscular ketamine must be administered in a CPSO-approved Out-of-Hospital Premises. Oral and intranasal ketamine do not require that premises approval. Esketamine (Spravato) is given intranasally under supervision.

Step 3: Document conventional treatment failures. The criteria are explicit about prior trials. For TRD, two oral antidepressants at maximally tolerated doses must have been tried and failed. For CRPS or neuropathic pain, multiple drug and non-drug treatments must be documented. Your physician builds this record into the request package.

Step 4: Submit the prior-authorization request. Your physician submits the request to WSIB's Drug Benefit Program. It must name the specific formulary, justify how the criteria are met, and document prior treatment failures. WSIB reviews it against the published criteria.

Step 5: Await WSIB's decision. WSIB reviews the request and decides. Timelines vary. Initial TRD approvals run about six months; renewals require evidence of response on validated scoring tools. If WSIB denies the request, you can appeal through the Workplace Safety and Insurance Appeals Tribunal (WSIAT).

Step 6: Treatment with WSIB reimbursement. If approved, the ketamine or esketamine is covered through the Drug Benefit Program. You receive treatment in the CPSO-approved facility, and WSIB reimburses the drug cost. Associated physician fees and psychotherapy components follow separate coverage rules within WSIB's health-care services framework.

Pro tip: Your WSIB case manager and a WSIB-affiliated physician are your key allies. A clinical package that anticipates the formulary criteria, including treatment failures documented in the right order, reduces back-and-forth with WSIB. You can ask your case manager to identify the relevant formulary before your physician submits the request.

---

How ATMA CENA supports Ontario workers and first responders

ATMA CENA's role for injured Ontario workers and first responders is clinical support, preparation, and integration within the three-phase model of psychedelic-assisted therapy. The medical prescription and CPSO compliance stay with the treating CPSO-registered physician. The psychotherapy component is delivered or supervised by a qualified regulated mental-health professional, such as a registered psychotherapist or registered psychologist. ATMA CENA supports your application; it does not submit WSIB prior-authorization requests and does not decide coverage.

Specifically, ATMA CENA can:

• Support the preparation phase before WSIB-funded ketamine treatment, including a thorough intake, trauma-informed assessment, and realistic expectation-setting for your specific work-related situation
• Provide integration support after ketamine sessions, coordinating with your existing WSIB-affiliated treating team rather than replacing it
• Help case managers and referring physicians understand what the preparation and integration components look like clinically, supporting documentation for prior authorization where appropriate
• Discuss eligibility for workers with accepted PTSD who may consider psilocybin or MDMA through Health Canada's case-by-case authorization pathway, given the 2025 approval-rate context

Through our CoCare program, ATMA CENA can partner with a worker's existing therapist, if they have the appropriate training, by building a service agreement. This lets workers keep an established therapeutic relationship in place, including a WSIB-affiliated psychologist or EAP therapist, while ATMA CENA supports the dosing-specific preparation and integration frame. Learn more about CoCare.

For Ontario workers, ATMA CENA provides psychedelic-assisted therapy and ketamine-assisted therapy through its member clinics. Where a treatment or component falls outside WSIB coverage, you can review ketamine therapy costs in Canada and find a member clinic. ATMA CENA's ketamine-assisted therapy is offered intranasally (Spravato and compounded), intramuscularly, and orally; ATMA CENA does not provide intravenous ketamine.

If you are an Ontario worker or first responder with a WSIB-accepted claim, book a free information call with ATMA CENA's clinical team. The call maps your accepted claim to the realistic WSIB prior-authorization pathway and discusses whether and how ATMA CENA can support your treatment.

---

Frequently asked questions

Does WSIB cover ketamine therapy in Ontario?

WSIB lists ketamine HCl injection and esketamine nasal spray (Spravato) on specific specialty formularies, with prior authorization, for three conditions: CRPS, refractory neuropathic pain, and treatment-resistant depression. Coverage is claim-by-claim and formulary-dependent, and WSIB decides each request. It is not a blanket benefit, and PTSD is not a listed indication. Psilocybin and MDMA are not covered on any WSIB formulary. Confirm the current listings and criteria with the board [WSIB 2025].

Is my PTSD claim covered if I'm a first responder in Ontario?

If you are a designated first responder under Ontario's Supporting Ontario's First Responders Act, 2016 (Bill 163), your PTSD is presumed work-related, which speeds up acceptance of your WSIB claim. That presumption establishes the diagnosis; it does not by itself approve any specific treatment. Ketamine or esketamine still requires a separate prior-authorization request that meets the relevant formulary criteria, and those drugs are listed for TRD, not PTSD directly [WSIB 2026].

What is the WSIB formulary for ketamine?

Ketamine HCl injection is listed on several WSIB specialty formularies covering musculoskeletal, central and peripheral nervous system, psychotraumatic, chronic pain disability, and serious injury pathways. Esketamine (Spravato) is listed on the psychotraumatic and serious injury formularies. All require prior authorization. The psychotraumatic formulary covers TRD that arises in a psychotraumatic injury context, not PTSD symptom reduction directly. Confirm the current formulary codes and criteria with the board [WSIB 2025].

Who is a designated first responder under Ontario's presumptive PTSD legislation?

WSIB Policy 15-03-13 lists categories including firefighters and fire investigators; police officers; paramedics and emergency medical attendants; 911 dispatch workers; nurses in direct patient care roles; correctional workers; provincial bailiffs and probation officers; special constables; and, added by later amendment, wildland firefighters and wildland fire investigators. Confirm the current designated categories with WSIB [WSIB 2026].

Can I get WSIB to cover ketamine for PTSD symptoms directly?

WSIB does not list PTSD as a covered indication for ketamine or esketamine. The Psychotraumatic formulary covers TRD in the context of a psychotraumatic work-related injury. A worker with both accepted PTSD and treatment-resistant depression may qualify through the TRD indication, but the prior authorization must document TRD specifically. The evidence for ketamine as a direct PTSD treatment is emerging but not yet guideline-supported [Feder 2021; CADTH 2023].

Does WSIB cover psilocybin or MDMA therapy?

No. Neither psilocybin nor MDMA is on any WSIB formulary. Access in Ontario requires Health Canada approval on a case-by-case basis, initiated by a physician, and is not guaranteed; approval rates dropped roughly 50% in 2025 [PsyCan 2025]. WSIB would not directly reimburse psilocybin or MDMA therapy accessed this way under the current 2026 structure.

What happens if WSIB denies my prior authorization for ketamine?

You can appeal a WSIB prior-authorization denial through the Workplace Safety and Insurance Appeals Tribunal (WSIAT). Additional clinical evidence, documentation of further conventional treatment failures, or specialist consultations can strengthen an appeal. Ontario's Office of the Worker Adviser (OWA) provides free representation for injured workers in WSIB proceedings.

Are there workers not covered by WSIB who might still qualify?

Workers outside mandatory WSIB coverage may have employers who opted into WSIB, or may have access through private insurance or out-of-pocket payment. WSIB formulary coverage applies only to workers with active WSIB claims. Workers without a WSIB claim but with private insurance should review their plan for coverage of psychedelic-assisted therapy.

How is ATMA CENA involved in the WSIB process?

ATMA CENA's clinical role is preparation and integration therapy. The prescribing physician and the CPSO-approved facility handle the medical administration of ketamine or esketamine. ATMA CENA's team supports the psychotherapy components of the three-phase model, and through the CoCare program can partner with a worker's appropriately trained existing therapist under a service agreement. ATMA CENA does not submit WSIB prior-authorization requests and does not decide coverage; the treating physician submits the request in coordination with the WSIB case manager.

---

Compliance disclaimer

Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label, regulated in Ontario by the College of Physicians and Surgeons of Ontario (CPSO). Intravenous and intramuscular ketamine administration requires a CPSO-approved Out-of-Hospital Premises. Esketamine (Spravato) is Health Canada-approved for treatment-resistant major depressive disorder in adults 18 to 64 only; it is not recommended for initiation in patients 65 and older, and it is not approved for PTSD in Canada. Canada's Drug Agency (CDA-AMC, formerly CADTH) recommended against public reimbursement of Spravato in December 2020, and it is not listed on Canadian public drug formularies. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy requires Health Canada approval on a case-by-case basis, initiated by a physician; approval is not guaranteed, and approval rates declined roughly 50% in 2025 [PsyCan 2025]. WSIB Ontario covers ketamine and esketamine on specific formularies with prior authorization only. Coverage is claim-by-claim and formulary-dependent; presumptive PTSD legislation (Ontario Bill 163) speeds up the underlying PTSD diagnosis for designated first responders but does not guarantee approval of specific treatments. WSIB adjudicates coverage; ATMA CENA supports the application and does not decide coverage. Advertising by Ontario registered psychotherapists is governed by CRPO Practice Standard 6.2. No testimonials are presented on this page. This article is for information only and is not medical, legal, financial, or tax advice. Confirm current coverage details with WSIB.

---

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

---

Sources

1. WSIB Ontario (2025). Drug Formulary Listing Decision: Ketamine and Esketamine. Workplace Safety and Insurance Board. https://www.wsib.ca/en/formulary-drug-listing-decisions
2. WSIB Ontario (2026). Posttraumatic Stress Disorder in First Responders and Other Designated Workers (Policy 15-03-13). Operational Policy Manual. https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
3. Ontario Legislative Assembly (2016). Bill 163, Supporting Ontario's First Responders Act (Posttraumatic Stress Disorder), 2016. https://www.ola.org/en/legislative-business/bills/parliament-41/session-1/bill-163
4. Ontario Legislative Assembly (2024). Bill 190, Working for Workers Five Act, 2024. https://www.ola.org/en/legislative-business/bills/parliament-43/session-1/bill-190
5. Feder, A., Costi, S., Rutter, S.B., et al. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry, 178(2), 193-202. PMID: 33397139. https://pubmed.ncbi.nlm.nih.gov/33397139/
6. Mitchell, J.M., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025-1033. https://www.nature.com/articles/s41591-021-01336-3
7. Mitchell, J.M., et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473-2480. PMID: 37709999. https://www.nature.com/articles/s41591-023-02565-4
8. Canadian Agency for Drugs and Technologies in Health (CADTH) (2023). Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK602384/
9. PsyCan (2025, September). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
10. Health Canada. Notice: Physician-initiated requests for psychedelic-assisted psychotherapy under Health Canada's case-by-case access pathway. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
11. CPSO (2019, December). Prescribing Drugs Policy. College of Physicians and Surgeons of Ontario. https://www.cpso.on.ca/Physicians/Policies-Guidance/Policies/Prescribing-Drugs
12. CPSO. Out-of-Hospital Premises Inspection Programme Overview. College of Physicians and Surgeons of Ontario. https://www.cpso.on.ca/Physicians/Your-Practice/Accreditation-Programs/Out-of-Hospital-Premises-Inspection-Program/Out-of-Hospital-Premises-Inspection-Program-Overvi
13. CRPO (2024, September). Practice Standard 6.2: Advertising. College of Registered Psychotherapists of Ontario. https://crpo.ca/practice-standards/business-practices/advertising/

---

Related articles

• WCB Alberta Psychedelic-Assisted Therapy (sibling provincial spoke)

---

Last updated: 2026-05-28. This article is reviewed every 3 months given regulatory sensitivity.